The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy

References

• Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(sup3):21–26. doi:10.1586/erv.10.30.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Herpes Zoster. N Engl J Med. 2013;369(3):255–63. doi:10.1056/NEJMcp1302674.
   PubMed Web of Science ®Google Scholar
• Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361–81.
   PubMed Web of Science ®Google Scholar
• Bollaerts K, Riera-Montes M, Heininger U, Hens N, Souverain A, Verstraeten T, Hartwig S. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol Infect. 2017;145(13):2666–77. doi:10.1017/S0950268817001546.
   PubMed Web of Science ®Google Scholar
• Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin. 2008;26(3):675–697, viii. doi:10.1016/j.ncl.2008.03.011.
   PubMed Web of Science ®Google Scholar
• Alicino C, Trucchi C, Paganino C, Barberis I, Boccalini S, Martinelli D, Pellizzari B, Bechini A, Orsi A, Bonanni P, et al. Incidence of herpes zoster and post-herpetic neuralgia in Italy: results from a 3-years population-based study. Hum Vaccin Immunother. 2017;13(2):399–404. doi:10.1080/21645515.2017.1264834.
   PubMed Web of Science ®Google Scholar
• Schmader K, Gnann JW Jr., Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl 2(Supplement_2)):S207–215. doi:10.1086/522152.
   PubMedGoogle Scholar
• Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A. Cost-effectiveness analysis of Herpes Zoster vaccination in Italian elderly persons. Int J Technol Assess Health Care. 2016;32(4):233–40. doi:10.1017/S0266462316000337.
   PubMed Web of Science ®Google Scholar
• Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, Di Marzo R, Volpi A. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10(1):230. doi:10.1186/1471-2334-10-230.
   PubMedGoogle Scholar
• Symoniak MR, Farrokh P, Gandhi MA, Slish JC. Herpes zoster subunit vaccine for the prevention of herpes zoster. Am J Health Syst Pharm. 2018;75(12):861–69. doi:10.2146/ajhp170399.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Vaccine scheduler - Herpes Zoster: recommended vaccinations. [accessed 2018 Oct 19]. https://vaccine-chedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=51&SelectedCountryIdByDisease=−1
   Google Scholar
• Gazetta Ufficiale della Republica Italiana. Piano Nazionale Prevenzione Vaccinale 2017–2018 (PNPV). 2017 [accessed 2018 Jul 23]. http://www.gazzettaufficiale.it/eli/id/2017/02/18/17A01195/sg
   Google Scholar
• Food and Drug Administration. Approval letter - Zostavax. 2018 Mar 21 [accessed 2018 Jul 23]. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm602293.pdf.
   Google Scholar
• Merck & Co. Inc. Zostavax (zoster vaccine live) prescribing information. [accessed 2017 Jun 15]. www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf
   Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent Herpes Zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84. doi:10.1056/NEJMoa051016.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney, D.J., Betts, R., Gelb, L., Guatelli, J.C., and Harbecke, R., for the Shingles Prevention Study G. Long-term persistence of Zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–09. doi:10.1093/cid/ciu918.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al. Persistence of the efficacy of Zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–28. doi:10.1093/cid/cis638.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ. Declining effectiveness of Herpes Zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213(12):1872–75. doi:10.1093/infdis/jiw047.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Approval Letter - SHINGRIX, 2017. 2017 Oct 20 [accessed 2018 Jul 23]. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM581750.pdf
   Google Scholar
• Health Canada. Shingrix product monograph including patient medication information. 2017 [accessed 2018 Dec 6]. https://pdf.hres.ca/dpd_pm/00041658.PDF
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2017. 2018 [accessed 2018 Oct 16]. http://www.pmda.go.jp/files/000224507.pdf#page=10
   Google Scholar
• Committee for Medicinal Products for Human Use (EMA - CHMP). Summary of opinion, Shingrix (EMA/CHMP/811150/2017). 2018 [accessed 2018 Oct 16]. https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-shingrix_en.pdf
   Google Scholar
• Australian Government - Department of health: therapeutic good administration. SHINGRIX recombinant Varicella Zoster virus glycoprotein E antigen vaccine 50 micrograms powder vial and suspension vial for suspension for injection. [accessed 2018 Oct 19]. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=5E9F90B4A76B269ACA258304004238C9&agid=(PrintDetailsPublic)&actionid=1
   Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted Herpes Zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of Herpes Zoster vaccines. Morb Mortal Wkly Rep. 2018;67(3):103–08. doi:10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS): updated recommendations on the use of Herpes Zoster vaccines. 2018 [accessed 2018 Oct 16]. https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html
   Google Scholar
• Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213–21. doi:10.1080/21645515.2017.1345399.
   PubMed Web of Science ®Google Scholar
• Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, Shiragami M. The potential public health impact of herpes zoster vaccination of people aged ≥ 50 years in Japan: results of a Markov model analysis. Dermatol Ther (Heidelb). 2018;8(2):269–84. doi:10.1007/s13555-018-0236-3.
   PubMed Web of Science ®Google Scholar
• Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. Vaccine. 2018;36(33):5037–45. doi:10.1016/j.vaccine.2018.07.005.
   PubMed Web of Science ®Google Scholar
• Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, Lorenc S, Curran D. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Hum Vaccin Immunother. 2018:1–11. doi:10.1080/21645515.2018.1509645.
   PubMed Web of Science ®Google Scholar
• Boccalini S, Alicino C, Martinelli D, Bechini A, Tiscione E, Pellizzari B, Prato R, Icardi G, Iannazzo S, Bonanni P. Clinical and economic impact of herpes zoster vaccination in elderly in Italy. Hum Vaccin Immunother. 2017;13(2):405–11. doi:10.1080/21645515.2017.1264832.
   PubMed Web of Science ®Google Scholar
• Istat - Istituto Nazionale di Statistica. Statistiche demografiche. [accessed 2018 Jul 23]. http://demo.istat.it/pop2017/index.html
   Google Scholar
• Istat - Istituto Nazionale di Statistica. Tavole di mortalità. [accessed 2018 Jul 23]. http://dati.istat.it/Index.aspx?DataSetCode=DCIS_MORTALITA1.
   Google Scholar
• World Health Organization. WHO database for deaths related to HZ for Italy (ICD10 – B02 codes). [accessed 2017 Nov 10]. http://data.euro.who.int/dmdb/
   Google Scholar
• Curtis L, Burns A. Unit costs of health and social care 2016. Canterbury (UK): Personal Social Services Research Unit, University of Kent; 2016.
   Google Scholar
• Le P, Rothberg MB. Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178(2):248–58. doi:10.1001/jamainternmed.2017.7431.
   PubMed Web of Science ®Google Scholar
• Robert Koch Institut. Mitteilung der Ständigen Impfkommission (STIKO) beim RKI. Wissenschaftliche Begründung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epidemiol Bull 2018;50:541–70.
   Google Scholar
• Ministero della Salute. Tariffe delle prestazioni di assistenza ospedaliera per acuti, per tipo di ricovero (Euro). 2018 [accessed 2018 Jul 23]. http://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=28/01/2013&redaz=13A00528&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001
   Google Scholar